Healthcare Industry News: Sidebranch Stent
News Release - October 26, 2009
Cappella, Inc. Expands Product Line & Commercial OperationsGALWAY, Ireland, Oct., 26--(HSMN NewsFeed)--Cappella, Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, announces that an additional diameter has been added to the Sideguard® platform. The current portfolio of Sideguard 2.5 and Sideguard 2.75 are now complemented with Sideguard 3.25. This additional size is intended to treat vessel lumen diameters of 2.75-3.25mm. According to Giuseppe M. Sangiorgi, MD, Director of the Interventional Cardiology Unit at the University Hospital Policlinico of Modena in Modena, Italy, “We are pleased with the Sideguard stent, which has demonstrated optimal wall apposition at the ostium and in the sidebranch. We believe that with this additional size we will be able to treat a majority of our coronary bifurcation cases.”
Cappella continues to expand its commercial operations in Europe with the addition of a direct sales force this month for the UK &Ireland. Cappella first received the CE mark for the Sideguard® Coronary Sidebranch Stent & Delivery System in April 2009. Since that time, it has pursued the expansion of the European sales activities through a direct & distributor-based sales organization. Cappella is currently active in Germany, Ireland, Italy, the Netherlands and the UK, with Austria & Switzerland to follow shortly. Commercial activities are also planned for France & Spain.
About Cappella, Inc.
Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. Cappella’s initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating the sidebranch of diseased coronary arteries first, rather than the main vessel. More importantly, it allows the preferred stent of choice for the main vessel. An optimal stent design specific to the anatomy of the sidebranch, combined with the qualities of Nitinol now provide a dynamic solution for treating sidebranch disease. Cappella Medical Devices Ltd., Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc. For more information, see: www.cappella-med.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.